Financial Performance - The total revenue for the year ended December 31, 2023, was RMB 16,972,276, representing an 18.9% increase from RMB 14,274,810 in 2022[2]. - The adjusted net profit for the year was RMB 130,542, compared to a loss of RMB 124,856 in the previous year, indicating a significant turnaround[2]. - The total Gross Merchandise Volume (GMV) reached RMB 1,740,923, up 21.3% from RMB 1,434,717 in 2022[2]. - The total GMV reached RMB 46,912 million, representing a year-on-year growth of 24.0%[11]. - The revenue from the self-operated business increased significantly from RMB 13,519.0 million for the year ended December 31, 2022, to RMB 16,036.2 million for the year ended December 31, 2023, primarily due to an expanded buyer base and increased buyer participation[32]. - The revenue from the platform business rose by 25.8% from RMB 694.2 million in 2022 to RMB 873.1 million in 2023, driven by the expansion of seller and buyer groups[32]. - The company reported a net loss of RMB 3,206,507 thousand for the year ended December 31, 2023, compared to a net loss of RMB 1,500,038 thousand in 2022[73]. - The adjusted net profit margin for the year ended December 31, 2023, was 0.8%, compared to 0.9% in 2022[47]. Customer and Market Growth - The cumulative registered buyer count exceeded 650,000, including approximately 401,000 pharmacies and 246,000 grassroots medical institutions[11]. - The average monthly active buyer count was 367,000, a year-on-year increase of 19.0%[11]. - The average monthly paying buyer count reached 343,000, reflecting a year-on-year growth of 21.1%[11]. - The company has seen a doubling in the number of customers and business scale in the traditional Chinese medicine tablet sector compared to 2022[6]. - About 50% of the platform's paying users are medical insurance designated stores, contributing over 60% of the GMV[14]. Operational Efficiency and Supply Chain - The company has established a digital supply chain system with 21 cities and 22 warehouses, enhancing operational efficiency and service quality[6]. - The company aims to improve same-city delivery efficiency, achieving half-day or same-day delivery in trial cities to reduce inventory pressure for downstream buyers[6]. - The average delivery time for orders to cities is about 40 hours and about 50 hours to towns, improving operational efficiency for pharmacies and healthcare institutions[16]. - The company has launched hundreds of logistics routes in provincial capital cities, achieving same-day delivery for many orders[16]. - The average number of orders per paying buyer rose from 27.3 to 29.6, an increase of 8.7%[11]. Product and Service Development - The platform offers approximately 3.6 million SKUs, with a significant increase of over 50% in the number of medical health product SKUs compared to the previous year[13]. - The platform provided over 110,000 SKUs of traditional Chinese medicine tablets in 2023, achieving sales of approximately RMB 13 million, representing a year-on-year growth of 113%[13]. - The company has completed the delivery of 60 product varieties under its own brand "Le Medicine Master," with 5 varieties achieving sales exceeding RMB 10 million, covering over 200,000 customers[18]. - The company has sold and installed 65 units of its self-developed "Micro Warehouse" system, which provides 24-hour uninterrupted service to pharmacies[20]. Strategic Initiatives and Future Plans - The company aims for a GMV scale of RMB 100 billion in the next 2-3 years, focusing on upstream layout and digital technology application[8]. - The company plans to deepen collaboration with industry participants to accelerate the digital transformation of the outpatient pharmaceutical industry[29]. - The company intends to invest in tens of thousands of digital testing devices nationwide to provide cost-effective and technologically advanced healthcare solutions[31]. - The company will continue to explore investment and acquisition opportunities in the pharmaceutical health sector to enhance its competitive edge[31]. Corporate Governance and Compliance - The company has complied with the Corporate Governance Code since its listing on June 28, 2023, and has held fewer than four board meetings during the reporting period[62]. - The Audit Committee has reviewed the audited consolidated financial statements for the year ending December 31, 2023, and discussed accounting policies and internal controls with the management[65]. - There are no significant litigations or arbitrations involving the group as of December 31, 2023[68]. - The company has implemented a 2023 share incentive plan, during which 270,000 shares were repurchased on the stock exchange[67]. Employee and Labor Relations - The total employee compensation cost for the year ended December 31, 2023, was RMB 1,064.3 million, an increase from RMB 988.6 million for the year ended December 31, 2022, with the percentage of total income decreasing from 6.9% to 6.3%[57]. - The company had a total of 6,306 employees as of December 31, 2023, with the largest segments being sales and marketing (2,988 employees) and operations (2,198 employees)[56]. - The company did not encounter any significant labor disputes or difficulties in hiring employees during the reporting period[57]. Financial Position and Cash Flow - Cash and cash equivalents decreased by 10.7% from RMB 835.4 million as of December 31, 2022, to RMB 745.7 million as of December 31, 2023, primarily due to increased use of notes payable for upstream supplier payments[48]. - Net cash generated from operating activities for the year ended December 31, 2023, was RMB 451.2 million, compared to RMB 98.2 million in 2022[49]. - The company recorded a net cash outflow from investing activities of RMB 792.9 million for the year ended December 31, 2023, compared to a net cash inflow of RMB 41.1 million in 2022[49]. - The capital debt ratio was 3.1% as of December 31, 2023, due to bank borrowings arising from bill discounting, compared to zero as of December 31, 2022[55]. Social Responsibility and Community Engagement - The company actively practices corporate social responsibility by ensuring drug supply and safety, supporting rural revitalization, and engaging in educational philanthropy[27]. - The company has received recognition from the Guangzhou Market Supervision Administration for its contributions to rural revitalization efforts[27]. - The company is committed to improving the educational environment in rural areas through donations to foundations[28].
药师帮(09885) - 2023 - 年度业绩